


Physician's reference checklist for Exjade®▼ (deferasirox) dosing and biological monitoring

▼This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance at www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing drugsafety.dublin@novartis.com or by calling (01) 2080 612.

This document highlights the main information about requirements for Exjade® dosing, dose adjustment and biological monitoring. For complete information about Exjade® dosing, dose adjustment and biological monitoring, please refer to Exjade® SmPC, which is available at www.medicines.ie.



*Further examples of dose calculation or adjustments are provided in the SmPC. Note: When switching from deferasirox DT to Exjade® FCT, a lower dose is required. As referenced in SmPC: Due to different pharmacokinetic profiles, a 30% lower dose of Exjade® FCT is needed in comparison to the recommended dose for deferasirox DTs.

**Dose reduction can also be considered.

§Refer to the SmPC for other dose adjustments/interruptions for renal and hepatic abnormalities, metabolic acidosis, SCARs, hypersensitivity reactions.

FCT= Film-Coated Tablets; LIC = Liver Iron Concentration; NTDT = Non-Transfusion Dependent Thalassemia; LLN = lower limit of the normal range